GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-03-26| R&DTechnology

Scientists Engineer Immune Cells with Cytokine to Stop Cancer Spread

by Sahana Shankar
Share To

One of the biggest hurdles in curing cancer is to prevent its spread to secondary sites (metastasis) and relapse. Improving the tumor microenvironment is an effective strategy to enhance tumor clearance. Addressing these two aspects, a team of scientists from the National Cancer Institute at NIH developed a new approach to immunotherapy to ‘prime’ organs to resist cancer spread.

 

New Study

In a new study published in Cell, authors investigated the immune repertoire in premetastatic organs, possible sites where cancer is likely to spread, and found that a type of immune cells called myeloid cells causes immune suppression and promotes metastasis in this niche. Strikingly, redesigning the myeloid cells to deliver anti-cancer drugs improves the immunogenicity of the premetastatic niche to fight the cancer.

Several studies show that there is an abundance of differentiated myeloid cells in specific organs, which are likely sites of metastasis. This indicates that the immune system can recognize the onset of metastasis and prepares these sites with its first line of defense. However, these myeloid cells suppress the immune response by limiting inflammation and activation of T cells and hence facilitate cancer spread. Previous studies by lead author Dr. Rosandra Kaplan discovered that these ‘premetastatic niches’ are made ready for cancer due to their unique myeloid cell population. Hence, they hypothesized that re-engineering the myeloid cells in the niche to deliver cytokines and activating the immune response could prevent metastasis.

Using a mouse model with rhabdomyosarcoma- a pediatric cancer of the muscle which spontaneously metastasizes to the lungs, the researchers analyzed the immune cell populations in the premetastatic lungs and found an enrichment of myeloid cell populations and reduction in dendritic cells, CD4+ T cells which promote immune suppression. Comparison of lung tissue from naïve and pre-metastatic mice showed that there was a dramatic shift in transcriptional program and upregulation of myeloid cells due to the tumor, demonstrating that adaptive immunity is turned off in the premetastatic niche.

 

Genetically-Engineered Myeloid Cells (GEMys)

Next, the team designed genetically-engineered myeloid cells- ‘GEMys’ to deliver immune activators to the pre-metastatic niche. Given that myeloid cells infiltrate the tumor and metastatic environments, GEMys with IL-12 cytokine restored T-cell activation and dendritic cell population in the premetastatic lungs, promoted pro-inflammatory cells, and hence reversed the immune suppression. Tumor mice treated with IL12-GEMys had reduced metastasis in the lungs and improved survival. The results were reproduced in a pancreatic cancer model of mice where IL12-GEMys reduced metastasis to the liver.

With further plans of clinical trials in adults, Dr.Kaplan said, “this is a novel approach to immunotherapy that appears to have promise as a potential treatment for metastatic cancer. We were excited to see that the GEMys ‘changed the conversation’ in the premetastatic niche. They were now telling other immune cells to get ready to fight the cancer.

A combination of chemotherapy with GEMys is likely to effectively fight cancer and metastasis, as evidenced by no tumor formation upon injecting tumor cells in mice cured by the combination therapy. The authors also synthesized GEMys from human cells and found similar improvements in inflammatory response in human cell lines.

The GEMys need to be validated for their safety and similar homing mechanism in humans. However, the study shows promise in identifying the mechanism of metastasis and preventing it. The dose of IL-2 cargo in the GEMys is small, and GEMys do not multiply in the body to cause IL-2 toxicity. These factors reassure the authors that IL-12 GEMys can be further developed for cell therapy against a wide variety of cancers.

Related Article: Singapore Researchers Design New C to G Base Editor to Correct Disease-Associated Mutations

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top